All In Biotech

Drug Trial Radar · NCT07185997

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Dec 17, 2025

Primary completion

Feb 2029

Study completion Dec 2030

Sponsor

Lead sponsor
ArriVent BioPharma, Inc.Industry
Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be randomized in a 1:1 ratio to treatment with firmonertinib or osimertinib or afatinib and will take the assigned dose daily.

Conditions

  • Non-Small-Cell Lung Cancer
  • Metastatic Non-Small-Cell Lung Cancer
  • Advanced Non-Small-Cell Lung Cancer
  • EGFR P-Loop and Alpha C-Helix Compressing
  • EGFR PACC
  • EGFR Uncommon Mutations

Interventions

  • FirmonertinibDrug

    240 mg oral, daily firmonertinib tablet

  • EGFR-TKI inhibitor based on investigator's choiceDrug

    osimertinib 80 mg oral, daily tablet OR afatinib 40 mg oral, daily tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) determined by blinded independent central review (BICR)Time frame: Until progression or death, assessed up to approximately 4 years
  2. Confirmed overall response rate (ORR) as determined by BICRTime frame: Until progression or death, assessed up to approximately 3 years

Locations

141 sites in 17 countries. Site status is shown where the registry gives one.

  • St. Jude Medical Center

    Fullerton, California · Recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Providence St. Joseph Hospital

    Orange, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • UCSF Medical Center-Mission Bay

    San Francisco, California · Recruiting

  • Kaiser Permanente Medical Center

    Vallejo, California · Recruiting

  • University of Colorado Health

    Aurora, Colorado · Recruiting

  • Illinois Cancer Specialists

    Arlington Heights, Illinois · Recruiting

  • University of Illinois Hospital and Health Sciences Systems

    Chicago, Illinois · Recruiting

  • Henry Ford Cancer Institute

    Detroit, Michigan · Recruiting

  • Northwell Health/R.J. Zuckerberg Cancer Center

    Lake Success, New York · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Ohio State University Hospitals

    Columbus, Ohio · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Texas Oncology

    Dallas, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Shenandoah Oncology, P.C.

    Winchester, Virginia · Recruiting

  • Swedish Cancer Institute

    Edmonds, Washington · Recruiting

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • GenesisCare North Shore Health Hub

    St Leonards, New South Wales, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • Alberta Health Services, Tom Baker Cancer Centre

    Calgary, Alberta, Canada · Recruiting

  • University of Alberta - Cross Cancer Institute (CCI)

    Edmonton, Alberta, Canada · Recruiting

  • BC Cancer Vancouver Centre

    Vancouver, British Columbia, Canada · Recruiting

  • Brampton Civic Hospital, William Osler Health Centre

    Brampton, Ontario, Canada · Recruiting

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada · Recruiting

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre - University Health Network

    Toronto, Ontario, Canada · Recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Cancer Hospital (PKUCH)/Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Chest Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, China · Recruiting

Showing 40 of 141 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.